Terns Pharmaceuticals

3 Biotechs Compete for the Same $108-Billion-Dollar Market
3 Biotechs Compete for the Same $108-Billion-Dollar Market
Motley Fool
NASH
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Fierce Biotech
NASH
Terns Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Flag link:
Spotlight – What is next in Nash
Spotlight – What is next in Nash
EP Vantage
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
IPO tracker: 2021 gets started with a flurry of new offerings
IPO tracker: 2021 gets started with a flurry of new offerings
Endpoints
IPOs
Sana Biotechnology
Sensei Biotherapeutics
Bolt Biotherapeutics
Immunocore
Terns Pharmaceuticals
Pharvaris
Vor Biopharma
Adagene
NexImmune
Biophytis
Gracell Biotechnologies
Cullinan Oncology
Flag link:
Eli Lilly's transpacific bosom buddy Terns bags late-round funding to drive NASH hopefuls through the clinic
Eli Lilly's transpacific bosom buddy Terns bags late-round funding to drive NASH hopefuls through the clinic
Endpoints
NASH
Terns Pharmaceuticals
Eli Lilly
Flag link:
FDA grants fast track status to Terns’s FXR agonist to treat NASH
FDA grants fast track status to Terns’s FXR agonist to treat NASH
Pharmaceutical Business Review
Terns Pharmaceuticals
FDA
NASH
TERN-101
fast track
Flag link: